Mk0653, ezetimibe    (DrugBank: Ezetimibe)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
260シトステロール血症3

260. シトステロール血症 [臨床試験数:13,薬物数:13(DrugBank:4),標的遺伝子数:1,標的パスウェイ数:1
Searched query = "Sitosterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 13 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00092898
(ClinicalTrials.gov)
October 200423/9/2004An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to An Ongoing Regimen of Ezetimibe 10 mg in Patients Homozygous SitosterolemiaLipid Metabolism, Inborn Errors;Heart DiseaseDrug: MK0653, ezetimibe;Drug: Comparator: placeboMerck Sharp & Dohme Corp.NULLCompleted18 Years85 YearsAll30Phase 3United States
2NCT00092820
(ClinicalTrials.gov)
February 12, 200123/9/2004Sitosterolemia Extension Study (0653-004)(COMPLETED)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous SitosterolemiaLipid Metabolism, Inborn Errors;Heart DiseaseDrug: MK0653, ezetimibe;Drug: Comparator: placeboMerck Sharp & Dohme Corp.NULLCompleted10 YearsN/AAll58Phase 3NULL
3NCT00092807
(ClinicalTrials.gov)
February 12, 200123/9/2004Sitosterolemia Extension Study (0653-003)(COMPLETED)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label ExtensionLipid Metabolism, Inborn Errors;Heart DiseaseDrug: MK0653, ezetimibe;Drug: Comparator: placeboMerck Sharp & Dohme Corp.NULLCompleted10 YearsN/AAll37Phase 3United States